ME20-S as a Potential Biomarker for the Evaluation of...
ME20-S as a Potential Biomarker for the Evaluation of Uveal Melanoma
Bande, Manuel F.; Santiago, Maria; Mera, Purificación; Piulats, Josep Maria; Blanco, Maria Jose; Rodríguez Álvarez, María Xosé; Capeans, Carmela; Pineiro, Antonio; Pardo, Maria
PURPOSE. We previously identified the presence of the melanocyte-specific secreted (ME20-S) glycoprotein in secretomes of uveal melanoma (UM) cultures. The aim of this study was to test for the presence and levels of ME20-S in the serum of patients with choroidal nevi and UM and correlate these levels with individual clinical data.
METHODS. Serum ME20-S levels were determined by ELISA in 111 patients distributed into four categories (53 choroidal nevi, 30 untreated UM, 11 10-year disease-free [DF] UM, 17 hepatic metastatic UM) and 32 age-and sex-matched controls. ME20-S levels were correlated with individual clinical data.
RESULTS. The UM and the metastatic groups showed significantly higher levels of serum ME20-S than the other groups (P < 0.001). ME20-S levels in the DF patients did not differ from those in the control group. In addition, log-transformed serum ME20-S levels showed a positive correlation with the thickness of the lesion mass in UM patients (regression coefficient 0.0689, 95% confidence interval 0.0689-0.1123, R-2 = 27.1%).
CONCLUSIONS. Elevated ME20-S serum levels are associated with tumor size and advanced stages of UM while low levels are characteristic of DF patients. ME20-S might be a promising serum marker for UM and useful for monitoring metastatic disease.